Ras-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy
A. Cuevas-Navarro, M. Wagner, R. Van, M. Swain, M. R. Allison, A. Cheng, S. Messing, D. K. Simanshu, M. J. Sale, F. McCormick, A. G. Stephen, P. Castel
This study identifies how pathogenic RIT1 mutations drive RAF-MAPK hyperactivation in Noonan syndrome, showing MEK inhibition can alleviate cardiac hypertrophy in a mouse model.
bioRxiv · Nov 2, 2022Biochemistry